In January 2023, the company will launch LENA Q51® the first Leukemia diagnostic tests able to test up to 51 genes mutations.
The medical community has historically defined, and treated cancer based on where it is found in the body, such as the breast, lung, or Leukemia.
The FDA has recently started to approve treatments based on the genetic makeup of cancer rather than where the cancer is located.
Sequencing a patient’s DNA continues to become faster and cheaper. More patients now have a window into their genetic codes to better understand how changes in their genes can lead to diseases like cancer.
Sequencing helps us to understand if a genetic mutation in, say, breast cancer is like a genetic mutation linked to colon cancer. If that is the case, a patient with this type of breast cancer may benefit from a treatment used for colon cancer, rather than one used to treat breast cancer. A very innovative path to successfully treat cancer and life-threatening illnesses.